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Objective: Intake of plant sterol (PS)-enriched foods effectively lowers plasma total- and LDL-cholesterol
concentrations while increasing plasma PS concentrations. The magnitude of this increase has not been
systematically assessed. This study aimed to investigate the effect of PS-enriched foods on plasma PS
concentrations by performing a meta-analysis of randomized controlled studies.
Methods: Published PS intervention studies reporting plasma PS concentrations were searched through
June 2012. Studies were selected that fulﬁlled pre-deﬁned in- and exclusion criteria. Data were extracted,
particularly on campesterol, sitosterol, total- and LDL-cholesterol. Random-effects models were used to
calculate net effects while weighing each study by the inverse of its variance. Potential sources of het-
erogeneity were investigated.
Results: The meta-analysis included data from 41 studies (55 strata) with in total 2084 subjects. The
average dose of PS from enriched foods was 1.6 g/d (range: 0.3e3.2 g/d). Plasma sitosterol and cam-
pesterol concentrations were increased by on average 2.24 mmol/L (31%) and 5.00 mmol/L (37%),
respectively, compared to control. Total- and LDL-cholesterol were reduced by on average 0.36 mmol/L
(5.9%) and 0.33 mmol/L (8.5%), respectively. The increase in sitosterol and campesterol was impacted by
the dose of PS, the baseline PS concentration and the PS composition of the test products. In the highest
PS dose category (2.0e3.2 g/d), increases in sitosterol and campesterol were on average 3.56 and
7.64 mmol/L, respectively.
Conclusion: Intake of PS-enriched foods increases plasma sitosterol and campesterol concentrations.
However, total PS remain below 1% of total sterols circulating in the blood.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
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Plant sterols (PS) are found in all foods of plant origin and are
structurally similar to cholesterol except for a slight difference in
their side chain, i.e. an additional ethyl or methyl group at C24.
The two major PS are sitosterol (24a-ethylcholesterol) and
campesterol (24a-methylcholesterol). Intake of PS-enriched
foods or supplements has been shown to effectively lower total
cholesterol (TC) and low-density lipoprotein (LDL)-cholesterol
concentrations [1,2]. Based on recent meta-analyses, a PS intake
of 2 g/d lowers LDL-cholesterol by on average 0.31e0.34 mmol/L
or 8e10% [3e5]. Elevated TC, and especially LDL-cholesterol, is
an established risk factor for cardiovascular disease (CVD) and
reducing cholesterol by dietary or drug interventions is known to
reduce the risk of CVD [6,7]. Hence, the cholesterol-lowering
properties of PS have been acknowledged by health associa-
tions such as the National Cholesterol Education Program Adult
Treatment Panel III [8], the American Heart Association [9], the
European Society of Cardiology and the European Atherosclerosis
Society [10].
PS lower plasma cholesterol by partly inhibiting cholesterol
absorption in the gut, mainly through competitionwith cholesterol
for micellar incorporation [11]. In contrast to cholesterol, PS
themselves are not bioavailable in signiﬁcant quantities as they are
excreted back from the intestinal mucosa into the intestinal lumen
by the heterodimer ATP-binding cassette (ABC) transporters
ABCG5/8 [12]. Only a small amount of dietary PS can be absorbed
and reaches the systemic circulation [13]. Furthermore, PS are not
synthesized in the human body. As such, circulating PS concen-
trations are w200 times lower compared to cholesterol concen-
trations in subjects consuming habitual diets [14].
When people consume the recommended dose of 2 g/d PS for
cholesterol-lowering purposes, they ingest 7e10 times more PS
than what is normally reached when consuming typical Western
diets which contain natural sources of PS such as vegetable oils,
cereals, vegetables, fruits, nuts and seeds. In these Western-type
diets, PS intakes range between 200 and 300 mg/d [15e18] whilst
vegetarians can consume up to 500e1000 mg/d of PS [19,20].
Despite the low bioavailability of PS, higher intakes of PS, especially
with enriched foods, do eventually result in increased plasma/
serum PS concentrations.
Recently, potential health concerns have been voiced related to
elevated PS concentrations following the intake of PS-enriched
foods mainly because of two reasons. First, patients with homo-
zygous sitosterolemia, a rare genetic disorder with mutations
in ABCG5/8 genes, have extremely elevated PS concentrations
(w500e1200 mmol/L) and often experience early onset of athero-
sclerosis independent of circulating cholesterol [21,22]. Second,
some, but not all, observational studies suggest a positive associa-
tion between modestly elevated PS concentrations and CVD risk
although the overall evidence, as summarized in a recent meta-
analysis, does not support such an association [23].Until now, the effect of PS-enriched food intake on plasma PS
concentrations has not yet been systematically investigated and the
size of the increase in circulating PS seems often overestimated by
referring to single studies. Therefore, the objective of this studywas
to perform a meta-analysis of randomized controlled studies to
estimate the absolute and relative change in plasma concentrations
of the main PS (i.e. sitosterol and campesterol) with and without
correction for TC concentrations after consumption of PS-enriched
food. Additionally, we estimated the change in plasma LDL-
cholesterol and TC concentrations in the selected PS intervention
studies. Furthermore, sources that could possibly explain some of
the between-study heterogeneity in changes in plasma PS and
cholesterol concentrations were investigated.2. Methods
2.1. Search strategy
To retrieve as many potentially relevant studies as possible, six
databases (Medline, Embase, Cab Abstracts, Food Science & Tech-
nology Abstracts, HCA Plus and Biosis) were systematically
searched through June 2012. For this, a search strategy was
developed including the Medical Subject Heading ‘phytosterols’
and the search terms ‘plant sterol* or phytosterol* or sitosterol* or
campesterol* or stigmasterol* or brassicasterol*’ and ‘blood* or
plasma or serum’, limited to humans and intervention studies were
possible. There was no restriction on language. For simplicity,
throughout this paper, the term “plasma” is used when referring to
plasma or serum depending onwhat has been used in the different
studies.2.2. Selection of studies
The following criteria for selecting eligible studies were pre-
deﬁned: (a) randomized placebo-controlled study in humans
(studies with (familial hypercholesterolemic) children were
allowed); (b) oral intake of PS-enriched foods or supplements as
active treatment (throughout this paper, the term “enriched
foods” encompasses also supplements which were used in only a
few studies); (c) absence of co-intervention from which con-
sumption of PS-enriched foods could not be isolated; (d) no
studies with colectomized patients or patients with hetero- or
homozygous sitosterolemia; (e) duration of treatment of at least
two weeks; (f) reporting of treatment effects on plasma sitosterol
and campesterol concentrations; (g) treatment with “common”
PS deﬁned as 4-desmethylsterols extracted from common vege-
table oils and no ferulated PS such as from rice bran oil and/or
sheanut oil; (h) dose of PS < 10 g/d; (i) composition of the
phytosterol mixture containing at least 80% PS (max 20% plant
stanols); (j) no treatment with ezetimibe; and (k) no conference
proceedings or duplicates.
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round, titles and abstracts were screened and those studies that
were obviously not fulﬁlling the pre-deﬁned selection criteria were
excluded, e.g. reviews, studies testing other ingredients than PS or
acute-effect studies. Because investigating effects on plasma PS is
usually not the primary objective in PS intervention studies, we did
not limit our search by only selecting studies that reported results on
plasma PS concentrations in their abstracts. In the second selection
round, full publications were read to judge eligibility of the studies.
A co-interventionwas deﬁned as any additional test ingredient next
to PS which was not added to the placebo intervention (e.g. the
portfolio diet containing soluble ﬁber, nuts, PS and soy protein vs. a
placebo diet). The source of fatty acid esters used to esterify PS into
PS esters was not considered as a co-intervention. The PS mixtures
used in the studies were not allowed to containmore than 20% plant
stanols [24] as stanols are known to reduce plasma PS concentra-
tions [25]. Studies including ezetimibe treatment were not selected
because ezetimibe is known to directly impact plasma PS concen-
trations via mechanisms in the gut. In case of indecisiveness, eligi-
bility was discussed amongst authors until consensus was reached.
2.3. Data extraction and transformation
Data were collected on (a) publication characteristics (reference
details and year of publication); (b) study characteristics (parallel or
crossover, sample size and study duration); (c) subject character-
istics (health status of subjects, mean age, mean BMI and gender
distribution); (d) treatment characteristics (PS dose, form of PS (free
or esteriﬁed PS), food format, PS source, etc); (e) measurement
characteristics (methodology used and serum or plasma); and (f)
outcome variables (plasma concentrations of sitosterol, campes-
terol (including those standardized for TC, e.g. expressed in mmol/
mmol TC), LDL-cholesterol, TC and high-density lipoprotein (HDL-)
cholesterol). We have not assessed the quality of the individual
studies because scoring of quality is rather subjective and excluding
studies based on this subjective scoringwas judged not appropriate.
For each of the outcome variables, data (mean absolute con-
centration and accompanying variance measure) were extracted at
baseline and at end-of-intervention. When outcome variables were
measured at different time points, the data closest to 4 weeks of
intervention were selected in order to standardize the intervention
duration amongst the studies. Original authors were contacted in
case the sitosterol and campesterol data were solely expressed as
concentrations corrected for TC [26e28].
In case concentrations of cholesterol were expressed in mg/dL,
datawere transformed to derive concentrations in mmol/L by using
the molecular weight of cholesterol (386.65 g/mol). In case con-
centrations of sitosterol and campesterol were expressed in mg/L,
mg/dL, mg/dL, ng/dL, mg/mL or ng/mL, data were transformed based
on the molecular weights of sitosterol (414.71 g/mol) or campes-
terol (400.68 g/mol) to derive concentrations in mmol/L. These
transformations were done both for means and SEs or SDs.
Control-adjusted absolute (mmol/L or mmol/L) and relative (%)
changes plus accompanying within-study SEs for sitosterol, cam-
pesterol, LDL-cholesterol, TC and HDL-cholesterol were calculated
for each study. For parallel studies, the absolute and relative
changes plus accompanying SEs were calculated based on the
average concentrations and variance measures at baseline and at
end-of-intervention of treatment and control groups. For crossover
studies that reported baseline data, the absolute and relative
changes were calculated similarly as for the parallel studies.
Otherwise, these were calculated based on the data at the end of
the treatment and control periods. In Supplemental Appendix 1, a
complete overview is provided of the formulas that were used to
transform the data.2.4. Statistical analysis
For each of the main outcome variables, a net effect was calcu-
lated according to a random-effects model while weighing the
studies by the inverse of their within-study variance (1/SE2) [29].
This was done for baseline concentrations, end-of-intervention
concentrations, absolute changes and relative changes. In contrast
to ﬁxed-effects models, random-effects models take into account
both the within-study variation as well as the large variation be-
tween studies and assume that the treatment effects of the indi-
vidual studies vary around some overall average treatment effect.
Funnel plots were developed with the effect sizes of all indi-
vidual studies expressed against their precisions (1/SE). These plots
visualize the likeliness of heterogeneity (when effect sizes fall
outside the conﬁdence limits) as well as the likeliness of publica-
tion bias (when clear holes in the funnel (i.e. asymmetry) are
detected). Heterogeneity was furthermore assessed by calculating
Q-statistics and I2-statistics [29] whereas publication bias was
analyzed according to Egger tests [30]. Forest plots were developed
for the absolute (mmol/L) and relative changes (%) in sitosterol and
campesterol.
Covariate analysis was performed to investigate the impact of
pre-speciﬁed covariates on the absolute and relative changes in
plasma PS and cholesterol concentrations after consumption of PS-
enriched foods. These covariates were dose of PS tested, baseline PS
or cholesterol concentration and PS composition (i.e. amount of
sitosterol or campesterol in the PS mixture of the test products).
Subgroup analysis was performed for determining differences be-
tween subgroups after stratiﬁcation based on the above mentioned
covariates. Also meta-regression analysis was performed for
assessing their correlations with the effect sizes found.
P-values below 0.05 were considered statistically signiﬁcant
based on two-sided hypothesis testing. All analyses were per-
formed with the statistical software package SAS version 9.2 (SAS
Institute, Inc., Cary, NC, USA). The PRISMA statement guidelines for
reporting in systematic reviews and meta-analyses were followed.
3. Results
3.1. Overview of included studies
With the systematic search, 1034 papers were identiﬁed. After
two selection rounds, 41 human intervention studies including 55
strata were judged eligible for inclusion in the current meta-
analysis (Fig. 1). Most of the studies were excluded because they
were no randomized controlled studies with human subjects,
investigated a different active ingredient or did not report plasma
or serum PS concentrations.
Of the 41 studies, 21 studies were parallel studies [26e28,31e
48], 19 were crossover studies [49e67] and 1 paper described a
parallel and a crossover study [68]. Non-standardized concentra-
tions of sitosterol and campesterol were available for all studies (55
strata). For 12 studies (14 strata), PS concentrations corrected for TC
concentrations (e.g. expressed in mmol/mmol TC) were available.
In total, 2084 subjects were included in the studies. The average
age of the subjects was 49.3 years (range: 10.5e60.1 years) and the
average BMI was 26.0 kg/m2 (range: 19.0e35.2 kg/m2). Six strata
included healthy or normocholesterolemic subjects, 39 strata
included hypercholesterolemic but otherwise healthy subjects and
10 strata included (hypercholesterolemic) subjects characterized as
metabolic syndrome patients, diabetics or statin users.
The median duration of studies was 28 days (range: 21e315
days). The PS dose tested was an average 1.6 g/d (median: 1.7 g/d;
range: 0.3e3.2 g/d). The majority of studies used (low-fat) spreads
(n ¼ 28) whilst others used dairy products like yoghurt, milk etc
Table 1
Overview of parallel studies.
Reference information Subject characteristics Treatment c
Sample size Gender
(% male)
Age (y) BMI
(kg/m2)
Free or
ester
Dos
(g/d
Control Active
Carr et al., 2009 16 16 50.0 37.1 25.5 Ester 1.8
Christiansen et al., 2001
stratum 1b
46 46 35.5 50.7 25.7 Free 1.5
Christiansen et al., 2001
stratum 2b
46 42 35.5 50.7 25.9 Free 3.0
Clifton et al., 2008 stratum 1b 39 37 56.6 55.2 26.8 Ester 1.6
Clifton et al., 2008 stratum 2b 39 39 48.7 54.5 26.9 Ester 1.6
Clifton et al., 2008 stratum 3b 39 36 56.0 54.2 26.7 Ester 1.6
Hansel et al., 2007 99 95 67.0 48.9 23.6 Ester 1.6
Hendriks et al. 2003b.c 96 89 48.6 48.0 24.9 Ester 1.6
Hernandez-Mijares
et al. 2010b,d
24 31 27.3 49.5 28.2 Ester 2.0
De Jong et al. 2006e 11 15 46.2 58.1 26.8 Ester 2.5
De Jong et al. 2008e 17 18 60.0 59.5 25.7 Ester 2.5
Korpela et al., 2006 82 82 21.3 57.3 27.0 Free 1.9
Kurokawa et al., 2008 27 32 69.9 44.7 23.2 Ester 0.8
Maki et al., 2001 stratum 1b,c 92 92 44.0 58.1 27.5 Ester 1.1
Maki et al., 2001 stratum 2b,c 92 40 42.4 58.4 27.3 Ester 2.2
Mannarino et al., 2008 56 60 44.0 50.1 25.0 Ester 1.6
Masuda et al., 2007 49 48 59.8 46.7 23.1 Ester 0.8
Neil et al. 2001b,c,d 29 29 41.9 51.6 26.0 Ester 2.5
Nittynen et al., 2007 study 2 14 12 57.7 45.9 26.0 Free 2.0
Plana et al. 2008c,e 40 43 41.0 51.4 26.7 Ester 1.6
Saito et al., 2006 stratum 1 17 16 100.0 38.4 23.6 Ester 0.3
Saito et al., 2006 stratum 2 17 16 100.0 39.2 23.6 Ester 0.4
Saito et al., 2006 stratum 3 17 17 100.0 38.7 23.9 Ester 0.5
Seki et al., 2003a 28 32 100.0 39.1 24.2 Ester 0.5
Seki et al., 2003b 11 11 100.0 41.2 24.2 Ester 1.3
Takeshita et al., 2007a 21 18 100.0 37.0 24.4 Esterg 0.4
Takeshita et al., 2008 15 14 20.7 59.4 21.9 Free 0.5
Varady et al., 2004 study 1 20 18 31.6 56.6 26.3 Ester 1.8
Varady et al., 2004 study 2 18 18 22.2 52.1 29.9 Ester 1.8
a PS dose expressed as free equivalents. Carr et al., 2009 reported the PS dose as esters; t
acids and 60% are PS.
b The following papers reported serum/plasma PS concentrations in a subset of the tot
(n ¼ 25), Hendriks et al. (n ¼ 83), Hernandez-Mijares et al. (n ¼ 34), Neil et al. (n ¼ 54)
c Cholesterol and plasma PS data are based on raw data.
d No average age was reported; thus, the average of the medians per group was used
e Non-standardized plasma PS data were obtained from original authors.
f The dose of PS was calculated by taking the average of 2, 2 and 1.65 g/d which were
g PS were mostly esteriﬁed PS.
Potentially relevant papers 
retrieved by systematic 
search or by hand searching 
N = 1034
Potentially relevant studies 
after first selection
N = 193
Human intervention studies 
included in the meta-analysis
N = 41
Studies excluded because:
• No RCT in humans (n=503)
• No oral intake of PS-enriched foods/ 
supplements (n=193)
• Intentional co-intervention (n=39)
• Colectomized or hetero/homozygous 
sitosterolemic patients (n=5)
• Treatment duration <2 weeks (n=10)
• Duplicates (n=91)
Studies excluded because:
• No RCT in humans with oral PS
intake (n=29)
• Intentional co-intervention (n=4)
• No plasma/serum campesterol and 
sitosterol data (n=78)
• Use of ferulated PS (n=1)
• Dose exceeding 10 g/d (n=2)
• Phytosterol mixture containing >20% 
plant stanols (n=5)
• Treatment with ezetimibe (n=1)
• Conference proceedings (n=16)
• Duplicates (n=16)
Fig. 1. Flow-chart of the study selection process.
R.T. Ras et al. / Atherosclerosis 230 (2013) 336e346 339(n ¼ 12) or other formats like dressing, mayonnaise, bread or
supplements (n ¼ 15). PS were in most cases esteriﬁed to different
fatty acids (n ¼ 43); only 12 strata used free PS as active ingredient.
Depending on the source of PS, PS mixtures typically contained
20e30% campesterol, 45e50% sitosterol and some other minor
sterols/stanols for soybean PS or 5e10% campesterol, 75e80%
sitosterol and some other minor sterols/stanols for tall oil PS [33].
Tables 1 and 2 show overviews of the parallel and crossover studies,
respectively, including sitosterol and campesterol data. In
Supplemental Appendix 2, an overview is provided summarizing
the blood cholesterol data.
3.2. Plasma PS outcomes
At baseline, plasma sitosterol and campesterol concentrations
were on average 6.92 and 13.07 mmol/L, respectively. After intake of
on average 1.6 g/d PS from enriched foods, plasma PS concentra-
tions were signiﬁcantly increased by on average 2.24 mmol/L for
sitosterol and 5.00 mmol/L for campesterol, compared to control.
Corresponding relative increases were 31.3% and 37.3%, respec-
tively. Total PS remained below 1% of total sterols circulating in theharacteristics Plasma plant sterols
e
)a
Food format Duration
(days)
Sitosterol Campesterol
Absolute
change
(mmol/L)
Relative
change
(%)
Absolute
change
(mmol/L)
Relative
change
(%)
a Capsules 28 0.97 16.3 3.69 42.5
Rapeseed oil margarine 90 0.97 33.0 1.09 12.3
Rapeseed oil margarine 90 1.02 36.6 1.52 21.2
Low-fat margarine 21 1.70 23.7 6.63 67.6
Low-fat margarine 21 6.36 78.9 1.37 11.4
Low-fat margarine 21 3.41 46.0 5.87 49.3
Low-fat fermented milk 42 1.81 27.3 0.75 14.1
Low-fat margarine 182 2.67 23.7 13.38 76.2
Low-fat milk 90 8.53 93.4 6.64 105.3
Low-fat margarine 112 4.10 36.4 25.50 95.3
Low-fat margarine 315 3.84 35.2 16.52 96.4
f Low-fat milk products 42 3.62 51.7 1.25 6.5
Dressing 84 2.41 50.0 4.99 40.0
Low-fat margarine 35 1.11 19.8 4.49 24.1
Low-fat margarine 35 2.36 34.4 9.53 43.6
Low-fat fermented milk 42 0.58 3.9 0.50 3.5
Drink 84 0.30 5.0 0.07 1.7
Margarine 56 1.17 20.4 7.21 71.5
Low-fat yogurt drink 56 9.65 56.9 6.99 29.6
Low-fat fermented milk 42 2.52 33.5 0.79 16.7
DAG-containing mayonnaise 28 0.42 5.5 1.60 9.4
DAG-containing mayonnaise 28 1.79 23.9 4.60 27.1
DAG-containing mayonnaise 28 0.93 10.5 3.80 19.8
Vegetable oil-based bread 28 0.72 16.1 2.25 39.5
Vegetable oil-based bread 28 0.96 23.2 3.74 78.4
DAG-containing mayonnaise 28 1.01 17.4 3.62 27.1
DAG-containing cooking oil 84 0.46 5.0 1.85 10.2
Low-fat margarine 56 0.95 28.9 2.94 38.4
Low-fat margarine 56 1.04 24.0 3.99 48.9
he amount of free equivalents was calculated assuming that 40% of PS esters are fatty
al number of subjects included in the study: Christiansen et al. (n ¼ 52), Clifton et al.
and Maki et al. (n ¼ 71).
.
the doses used in the different foods.
Table 2
Overview of crossover studies.
Reference information Subject characteristics Treatment characteristics Plasma plant sterols
Sample
size
Gender
(% male)
Age (y) BMI
(kg/m2)
Free or
ester
Dose
(g/d)a
Food format Duration
(days)
Sitosterol Campesterol
Absolute
change
(mmol/L)
Relative
change (%)
Absolute
change
(mmol/L)
Relative
change (%)
AbumWeis et al., 2006 stratum 1 30 e 59.0 28.0 Free 1.7 Margarine 29 2.90 41.4 0.80 4.3
AbumWeis et al., 2006 stratum 2 30 e 59.0 28.0 Ester 1.7 Margarine 29 1.70 24.3 5.50 29.6
Amundsen et al. 2004b 41 46.3 10.5 19.0 Ester 1.6 Low-fat margarine 56 4.00 33.4 10.37 76.3
Casas-Agustench et al., 2012 43 51.2 49.0 26.6 Ester 2.0 Skimmed milk 28 12.01 90.6 9.22 62.8
Clifton et al., 2004 stratum 1c 58 39.7 54.0 26.2 Ester 1.6 Bread 21 2.70 31.6 4.09 44.1
Clifton et al., 2004 stratum 2c 58 39.7 54.0 26.2 Ester 1.6 Milk 21 2.34 27.4 4.89 52.7
Demonty et al., 2006 21 52.4 54.2 25.9 Ester 1.7 Orange juice 29 1.38 19.9 8.19 67.9
Hallikainen et al., 2000 34 47.6d 48.8 24.9 Ester 2.0 Margarine 28 2.00 24.4 6.89 35.8
Heggen et al., 2010 stratum 1 59 72.9 52.0 24.8 ester 2.0 Low-fat margarine 28 5.73 83.1 1.10 4.8
Heggen et al., 2010 stratum 2 59 72.9 52.0 24.8 Ester 2.0 Low-fat margarine 28 5.97 86.5 15.05 65.6
Houweling et al., 2009 study 1 41 100.0 50.4 27.8 Ester 2.0 Low-fat margarine 28 2.77 23.1 4.25 21.0
Houweling et al., 2009 study 2 41 100.0 52.1 29.0 Ester 2.0 Low-fat margarine 28 2.71 34.7 3.23 27.0
Jakulj et al., 2005 39 87.5 55.5 25.9 Ester 2.0 Low-fat margarine 28 1.91 20.7 10.96 78.7
Jones et al., 2000 15 100.0 e e Ester 1.8 Low-fat margarine 21 2.50 29.1 8.60 67.3
Kratz et al., 2007 10 e 30.0 21.9 Ester 2.0 Low-fat margarine 42 0.90 12.5 4.00 24.0
Lau et al., 2005 study 1b 14 35.7 54.5 30.2 Free 1.8 Margarine 21 0.84 34.1 0.31 8.6
Lau et al., 2005 study 2b 15 40.0 55.1 26.9 Free 1.8 Margarine 21 0.66 20.3 0.72 9.3
Mussner et al., 2002 62 38.7 42.0 24.0 Ester 1.8 Margarine 21 1.57 35.3 6.96 78.2
Myrie et al., 2012 15 53.3 33.8 30.4 Free 1.6 Capsules 29 0.21 3.0 2.84 22.8
Nittynen et al., 2007 study 1 15 100.0 41.0 26.0 Free 1.0 Low-fat yogurt drink 28 2.41 38.5 5.99 34.3
Ooi et al., 2007 9 100.0 60.1 35.2 Ester 2.0 Breakfast cereal and
margarine
28 1.95 44.3 5.19 80.6
Rudkowska et al., 2008 stratum 1 26 e 59.6 26.4 Ester 1.6 Low-fat yogurt 30 0.85 42.7 2.74 27.8
Rudkowska et al., 2008 stratum 2 26 e 59.6 26.4 Ester 1.6 Low-fat yogurt 30 1.02 55.5 3.87 39.0
Takeshita et al., 2007b 14 0.0 52.2 23.0 Free 0.6 DAG-containing
cooking oil
28 1.44 22.2 4.38 33.3
Vanstone et al., 2002 15 60.0 47.8 30.8 Free 1.8 Butter 21 2.40 28.3 13.10 90.9
Weststrate et al. 1998e 40 50.0 46.2 24.2 Esterf 3.2 Margarine 21 2.89 37.5 12.23 71.0
a PS dose expressed as free equivalents.
b The following papers reported serum PS concentrations in a subset of the total number of subjects included in the study: Amundsen et al. (n ¼ 29) and Lau et al. (n ¼ 27).
c Incomplete crossover design: not all subjects received all treatments (ncontrol ¼ 58, nbread ¼ 36, nmilk ¼ 40).
d Gender distribution is based on 42 subjects (8 dropped out).
e Age, gender, cholesterol and plasma PS data are based on raw data of n ¼ 40. BMI is based on total n in the study (n ¼ 100).
f PS were mostly esteriﬁed PS.
R.T. Ras et al. / Atherosclerosis 230 (2013) 336e346340blood. When corrected for TC, sitosterol concentrations signiﬁ-
cantly increased by on average 0.59 mmol/mmol TC (41.7%) and
campesterol by on average 1.34 mmol/mmol TC (60.8%). Table 3
gives an overview of the weighed net effects. Forest plots of the
absolute changes in sitosterol and campesterol are shown in Fig. 2.
Forest plots of the relative changes are provided in Supplemental
Appendix 3.Table 3
Weighed net effects (baseline, end-of-intervention, absolute change and relative chan
cholesterol, based on random effects models.
Parameter Unit Baseline concentrationa Con
PS i
b-Sitosterol mmol/L 6.92 (6.23; 7.61) 9.2
mmol/mmol TCc 1.22 (0.88; 1.56) 1.7
Campesterol mmol/L 13.07 (11.65; 14.48) 18.1
mmol/mmol TCc 2.10 (1.63; 2.56) 3.3
LDL-cholesterol mmol/L 3.90 (3.76; 4.03) 3.5
Total cholesterol mmol/L 6.04 (5.90; 6.18) 5.6
HDL-cholesterol mmol/L 1.42 (1.37; 1.47) 1.4
Expressed as means (95%CI).
a The weighed average baseline concentration was calculated based on the baseline
studies, the baseline concentrations were used when reported; otherwise the end-of-in
b The weighed average concentration after PS intervention was calculated based on t
studies, and based on the end-of-intervention concentrations of the active periods in ca
c The weighted net effects of the PS to cholesterol ratios were based on only 12 studie
concentrations. The non-standardized weighed net effects are based on 41 studies (55 sFor both absolute and relative changes in sitosterol and cam-
pesterol concentrations, there was signiﬁcant heterogeneity be-
tween the studies as assessed by inspecting funnel plots (a
considerable number of studies reported effects outside the conﬁ-
dence limits) and calculating I2-statistics (P-value<0.05)
(Supplemental Appendix 4). Furthermore, regression analysis of
the standard normal deviate as a function of the precision and thege) of plasma sitosterol, campesterol, LDL-cholesterol, total cholesterol and HDL-
centration after
nterventionb
Absolute change vs. placebo Relative change vs.
placebo (%)
9 (8.20; 10.38) 2.24 (1.71; 2.77) 31.3 (26.0; 36.7)
7 (1.14; 2.41) 0.59 (0.25; 0.92) 41.7 (31.0; 52.5)
8 (15.99; 20.38) 5.00 (3.86; 6.14) 37.3 (29.3; 45.3)
9 (2.43; 4.34) 1.34 (0.83; 1.85) 60.8 (44.7; 76.9)
9 (3.47; 3.72) 0.33 (0.37; 0.30) 8.5 (9.2; 7.7)
9 (5.56; 5.82) 0.36 (0.40; 0.32) 5.9 (6.5; 5.3)
1 (1.36; 1.47) 0.00 (0.02; 0.01) 0.1 (1.1; 0.9)
concentrations in the active and placebo groups for parallel studies. For crossover
tervention concentrations of the placebo periods were used.
he concentrations after PS intervention in the active treatment groups for parallel
se of crossover studies.
s (14 strata) that reported plasma PS concentrations corrected for total cholesterol
trata).
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Fig. 2. Forest plots of the absolute (mmol/L) changes in plasma sitosterol and campesterol concentrations.
R.T. Ras et al. / Atherosclerosis 230 (2013) 336e346 341asymmetrical shape of the funnel plots indicated that publication
bias was likely present in all sitosterol and campesterol analyses
(Egger test: P-value (intercept) < 0.05; studies reporting relatively
small increases in plasma PS concentrations at the bottom of the
funnel seemed lacking).
3.3. Plasma cholesterol outcomes
LDL-cholesterol and TC concentrations at baseline were on
average 3.90 and 6.04 mmol/L, respectively. LDL-cholesterol was
reduced by on average 0.33 mmol/L (8.5%) and TC by 0.36 mmol/L
(5.9%) with an average PS intake of 1.6 g/d, compared to control
(Table 3). Heterogeneity was statistically signiﬁcant for absolute
changes in TC (P-value ¼ 0.029) whereas it was not signiﬁcant for
absolute and relative changes in LDL-cholesterol and for relative
changes in TC (P-value >0.05). The heterogeneity in cholesterol
changes was clearly less obvious as compared to the heterogeneity
in plasma PS changes. Visual inspection of symmetrical funnel plots
as well as the outcomes of the Egger tests (P-value of intercept
ranging between 0.397 and 0.613) suggested absence of publication
bias for LDL-cholesterol and TC (Supplemental Appendix 5). HDL-
cholesterol did not change upon PS intervention (0.00 mmol/L
or 0.1%; Table 3).
3.4. Covariate analyses
Meta-regression analyses revealed that dose of PS, baseline PS
concentration and PS composition signiﬁcantly impacted the ab-
solute changes in plasma PS concentrations. Absolute increases in
sitosterol and campesterol were larger in studies with higher doses
of PS (b ¼ 1.02, P-value ¼ 0.014 and b ¼ 2.37, P-value ¼ 0.009,respectively), with higher average baseline concentrations
(b ¼ 0.39, P-value <0.001 and b ¼ 0.35, P-value <0.001, respec-
tively), and with higher amount of either sitosterol or campesterol
in the PS mixture (b ¼ 0.06, P-value ¼ 0.004 and b ¼ 0.27,
P-value ¼ <0.001, respectively). When looking at the relative
changes, the impact of baseline concentrations was, as expected,
not present anymore. Subgroup analyses showed comparable re-
sults except for a weaker (non-signiﬁcant) impact of PS composi-
tion on absolute and relative changes in plasma sitosterol and a
weaker impact of PS dose on relative changes in plasma campes-
terol. In the subgroup with the highest-dose studies (2.0e3.2 g/
d PS), increases in sitosterol and campesterol were on average
3.56 mmol/L (42.2%) and 7.64 mmol/L (47.9%), respectively. The re-
sults of the covariate analyses are shown in Table 4.
3.5. Post hoc analyses
To investigate the shape of the doseeresponse relationship be-
tween PS doses and changes in plasma PS, we established contin-
uous doseeresponse curves based on ﬁrst-order elimination
functions. A slight tapering-off effect seemed present for changes in
both plasma sitosterol (Fig. 3, Panel A) and campesterol concen-
trations (Fig. 3, Panel B). It should however be noted that these
curves are severely limited by the heterogeneous distribution of the
observed changes across the range of doses included.
In addition, we investigated the impact of food format (dairy-
type foods vs. (low-fat) margarine), blood matrix (serum vs.
plasma), subjects’ health status (diabetics/metabolic syndrome
patients vs. hypercholesteromic subjects vs. normocholester-
olemic/healthy subjects) and study duration (4 weeks vs. >4
weeks) on the changes in plasma PS concentrations. No signiﬁcant
Table 4
Results of the covariate analysis for absolute and relative changes in plasma sitosterol, campesterol, LDL-cholesterol and total cholesterol concentrations.
Trial
characteristic
Stratiﬁcation variable No of
study
arms
Subgroup analysis Meta-regression
analysis
Subgroup analysis Meta-regression
analysis
Change vs.
placebo
95% CI P-value
between
subgroupsa
b P-value
meta-
regressionb
Change vs.
placebo
95% CI P-value
between
subgroupsa
b P-value
meta-
regressionb
Absolute change (mmol/L) in sitosterol Relative change (%) in sitosterol
Baseline
concentration
Below median
(6.9 mmol/L)
26 1.38 (0.71; 2.05) <0.001 0.39 <0.001 28.1 (20.3; 36.0) 0.284 0.4 0.677
Above median
(>6.9 mmol/L)
29 3.08 (2.41; 3.76) 33.9 (26.8; 41.1)
Dose of PS 0.3 g/d and 1.5 g/d 13 1.08 (0.13; 2.04) 0.001 1.02 0.014 18.7 (9.0; 28.5) 0.002 12.0 0.002
>1.5 g/d and <2.0 g/d 25 2.00 (1.31; 2.69) 30.0 (22.9; 37.2)
2.0 g/d and 3.2 g/d 17 3.56 (2.68; 4.44) 42.2 (33.6; 50.9)
PS composition
(% sitosterol)
Below median (<50%) 27 1.81 (1.06; 2.56) 0.128 0.06 0.004 26.8 (19.1; 34.4) 0.107 0.8 <0.001
Above median (50%) 28 2.62 (1.90; 3.34) 35.4 (28.2; 42.6)
Absolute change (mmol/L) in campesterol Relative change (%) in campesterol
Baseline
concentration
Below median
(12.6 mmol/L)
28 3.44 (1.97; 4.91) 0.003 0.35 <0.001 35.8 (24.3; 47.4) 0.724 0.4 0.572
Above median
(>12.6 mmol/L)
27 6.64 (5.10; 8.17) 38.7 (27.6; 49.8)
Dose of PS 0.3 g/d and 1.5 g/d 13 3.03 (0.92; 5.15) 0.003 2.37 0.009 24.1 (8.7; 39.5) 0.084 12.8 0.042
>1.5 g/d and <2.0 g/d 25 4.26 (2.72; 5.79) 37.4 (26.0; 48.9)
2.0 g/d and 3.2 g/d 17 7.64 (5.72; 9.55) 47.9 (33.8; 62.0)
PS composition
(% campesterol)
Below median (<25%) 27 3.11 (1.67; 4.54) <0.001 0.27 <0.001 26.4 (15.9; 37.0) 0.005 1.6 0.001
Above median (25%) 28 6.85 (5.39; 8.31) 47.5 (37.1; 58.0)
Absolute change (mmol/L) in LDL-cholesterol Relative change (%) in LDL-cholesterol
Baseline
concentration
Below median
(3.9 mmol/L)
26 0.26 (0.31; 0.21) 0.001 0.10 0.011 7.4 (8.7; 6.0) 0.057 0.6 0.559
Above median
(>3.9 mmol/L)
29 0.37 (0.41; 0.34) 8.9 (9.8; 8.1)
Dose of PS 0.3 g/d and 1.5 g/d 13 0.25 (0.32; 0.18) 0.038 0.07 0.017 6.6 (8.3; 4.8) 0.052 1.7 0.015
>1.5 g/d and<2.0 g/d 25 0.35 (0.40; 0.30) 8.8 (9.8; 7.7)
2.0 g/d and 3.2 g/d 17 0.35 (0.40; 0.31) 9.1 (10.2; 7.9)
Absolute change (mmol/L) in total cholesterol Relative change (%) in total cholesterol
Baseline
concentration
Below median
(6.0 mmol/L)
26 0.26 (0.32; 0.20) <0.001 0.14 <0.001 4.6 (5.6; 3.6) 0.004 1.3 0.064
Above median
(>6.0 mmol/L)
29 0.41 (0.45; 0.37) 6.4 (7.0; 5.8)
Dose of PS 0.3 g/d and 1.5 g/d 13 0.28 (0.36; 0.20) 0.039 0.07 0.034 4.6 (5.8; 3.3) 0.010 1.2 0.011
>1.5 g/d and <2.0 g/d 25 0.35 (0.41; 0.30) 5.7 (6.5; 4.9)
2.0 g/d and 3.2 g/d 17 0.40 (0.46; 0.35) 6.8 (7.6; 6.0)
a P-value between subgroups <0.05 indicates a signiﬁcant difference in pooled effect size between subgroups.
b P-value meta-regression <0.05 indicates a signiﬁcant correlation between the variable under investigation and the effect sizes.
R.T. Ras et al. / Atherosclerosis 230 (2013) 336e346342impact of these potential covariates on the absolute and relative
changes in plasma PS concentrations could be detected (P-value
>0.05). Regarding duration, we additionally analyzed whether
there was a statistically signiﬁcant difference between halfway and
end-of-intervention plasma PS changes in studies that reported
plasma PS concentrations at several time points [27,32,44,46];
again, no signiﬁcant impact of duration was detected (P > 0.05).
Covariate analyses furthermore revealed that absolute and
relative reductions in LDL-cholesterol and TC were larger with
higher doses of PS and that absolute reductions in LDL-cholesterol
and TC were larger with higher respective baseline concentrations.
The impact of baseline cholesterol concentrations on the relative
changes was weaker, especially for LDL-cholesterol (see Table 4).
At last, we analyzed whether the relative changes in LDL-
cholesterol were related to the relative changes in plasma PS
(Supplemental Appendix 6). In fact, no such correlation was found.
Perhaps differences in metabolic fates between cholesterol and PS,
e.g. circulating cholesterol is derived from synthesis and absorption
whereas circulating PS can only be obtained through absorption,
provide an explanation for this ﬁnding. Also, the considerable
heterogeneity in plasma PS changes might have blurred the asso-
ciation with LDL-cholesterol.4. Discussion
For the ﬁrst time, the effect of PS-enriched food intake on
plasma PS concentrations was systematically investigated by
reviewing available data from published PS intervention studies.
We observed signiﬁcant increases in plasma sitosterol and cam-
pesterol concentrations after intake of PS-enriched foods, as was
expected. The average increases in plasma sitosterol and campes-
terol concentrations were 2.24 mmol/L (31%) and 5.00 mmol/L (37%),
respectively, with an average intake of 1.6 g/d PS. In the highest PS
dose category (2.0e3.2 g/d), the average absolute increases were
3.56 mmol/L (42%) and 7.64 mmol/L (48%), respectively. The baseline
plasma sitosterol and campesterol concentrations that we observed
in the current meta-analysis (6.9 and 13.1 mmol/L, respectively)
were comparable to what has previously been reported by Chan
et al. [14]. In this review including data of 45 studies, average
baseline concentrations for sitosterol and campesterol in the gen-
eral population were 7.9 and 14.2 mmol/L, respectively. We
furthermore observed an average reduction in LDL-cholesterol of
0.33 mmol/L (8.5%) which is similar to the pooled LDL-cholesterol-
lowering effect expected for 1.6 g/d of PS based on several recent
meta-analyses [3e5]. So, despite the smaller number of studies
AB
-40
-20
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5 3 3.5
C
a
h
n
g
e
 
i
n
 
p
l
a
s
m
a
 
c
a
m
p
e
s
t
e
r
o
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
%
)
Dose of PS (g/d)
Observed changes Predicted curve Lowest PS dose Highest PS dose
-40
-20
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5 3 3.5
C
a
h
n
g
e
 
i
n
 
p
l
a
s
m
a
 
s
i
t
o
s
t
e
r
o
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
%
)
Dose of PS (g/d)
Observed changes Predicted curve Lowest PS dose Highest PS dose
Fig. 3. Doseeresponse relationship between doses of PS and relative (%) changes in
plasma sitosterol (Panel A) and campesterol (Panel B) concentrations. A ﬁrst-order
elimination curve was plotted through the observed changes.
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analysis compared to the more extensive cholesterol-lowering ef-
ﬁcacy meta-analyses, our selection of studies seems representative
for a broader range of studies. Also, with no less than 41 studies, a
robust overview of the available literature has been developed.
In the current meta-analysis, the change in plasma PS concen-
trations was related to the dose of PS consumed per day, i.e. the
higher the dose, the larger the increase in both sitosterol and
campesterol concentrations. For PS-induced cholesterol-lowering,
it is known that the decrease in plasma cholesterol concentrations
would reach a plateau with increasing dose of PS due to saturable
processes in cholesterol uptake and transport and subsequent
feedback on cholesterol synthesis. Whether such tapering-off effect
exists for plasma PS concentrations is yet unclear. In an attempt to
investigate this, we established continuous doseeresponse curves
for the relationship between PS doses and changes in plasma PS
concentrations. These curves suggest that some tapering-off might
exist although the maximal increase in plasma PS will likely be
reached at doses higher than 3.2 g/d which was the highest dose
tested in our meta-analysis. Studies investigating higher PS doses
are scarce. Only two studies tested PS doses exceeding 3 g/d and
reported serum PS concentrations. The study by Davidson et al. [69]
tested PS intakes of 3, 6 and 9 g/d from enriched foods, but only
reported medians and ranges of plasma PS concentrations. Based
on their analysis, the increase in serum PS did not signiﬁcantly
differ between the three PS doses, except for the TC-standardized
increase in campesterol. Noteworthy, even with the highest dose
of PS (9 g/d), overall absolute PS concentrations remained below
2 mg/dL (w50 mmol/L). Another study by Tuomilehto et al. [70]
investigated increasing intakes of PS (1.25, 2.5 and 5 g/d) together
with a mix of minerals during three consecutive 5-week periods.Serum sitosterol concentrations increased in a dose-dependent
manner whereas no dose-dependent increase was observed in
serum campesterol concentrations. From these data, together with
the ﬁndings of the current meta-analysis which included studies
investigating PS doses in the range of 0.3e3.2 g/d, no ﬁrm con-
clusions can be drawn on the doseeresponse behavior for plasma
PS concentrations at higher PS doses (>3 g/d). The composition of
the PSmixture, and related to this the PS source, also inﬂuenced the
magnitude of the increase in plasma sitosterol and campesterol
concentrations. For instance, studies that used PS derived from tall
oil which contains less campesterol (w5e10%) and more sitosterol
(75e80%) compared to e.g. soybean oil (20e30% campesterol and
45e50% sitosterol), showed smaller increases in plasma campes-
terol concentrations whereas increases in sitosterol concentrations
were larger.
The concentrations of PS at baseline also seemed to explain part
of the heterogeneity observed between different study results; in
studies with higher average baseline PS concentrations, the abso-
lute increase in plasma sitosterol and campesterol concentrations
was larger compared to studies with lower average baseline con-
centrations. It could be that subjects with higher cholesterol/PS
absorption efﬁciency (as indicated by higher baseline PS concen-
trations) are likely to absorb more PS when on PS intervention.
Alternatively, the use of different analytical techniques to measure
plasma PS concentrations could potentially have caused differences
(systematic errors) in baseline concentrations and thus in changes
upon intervention. This latter hypothesis is supported by the
observation that baseline concentrations had no impact on relative
changes in plasma PS concentrations which are less affected by
systematic errors. Interestingly, Hendriks et al. [35] found that in
subjects with the highest baseline PS concentrations, the average
relative increase after one year consumption of PS-enriched
margarine was even smaller as compared to subjects with lower
baseline PS concentrations. This might suggest that some kind of
feedbackmechanism arises (e.g. upregulation of ABCG5/8) when PS
are consumed for a longer period of time. Indeed, based on studies
that reported plasma PS concentrations at different time points
[27,32,44,46], the increase in plasma sitosterol and campesterol
seemed to stabilize over time, which we conﬁrmed in post hoc
analyses. For example, in the study by de Jong et al. [27], plasma
sitosterol and campesterol concentrations were similar after 45
weeks and 85 weeks of PS intervention.
The plasma PS concentrations that we observed in our meta-
analysis are much lower than those reported in patients with ho-
mozygous sitosterolemia. Patients with this disease display plasma
PS concentrations in the range of w500e1200 mmol/L (w20e
50 mg/dL) [22]. This is 20e45 times higher than the average total
plasma PS concentration after intake of PS-enriched foods observed
in the current meta-analysis. In this respect, the PS-induced in-
crease in plasma PS can be considered modest and is not reaching
the levels seen in homozygous sitosterolemics. Subjects with het-
erozygous sitosterolemia do not have such elevated plasma PS
concentrations although their plasma PS concentrations are
somewhat elevated (35e37%) compared to healthy controls [71].
These elevated concentrations are of the same order of magnitude
as the increases in plasma sitosterol and campesterol concentra-
tions after PS-enriched food intake seen in our study. Several
studies [60,63,72,73] investigated what would happen if subjects
with heterozygous sitosterolemia would regularly consume PS-
enriched foods and found that these subjects showed similar
plasma PS responses as compared to control subjects.
Recent evidence suggests that moderate, lifelong elevations in
plasma PS concentrations in heterozygous sitosterolemics being
carriers of the ABCG8-G574R variant are not associated with
increased intima-media thickness (IMT). These subjects even
R.T. Ras et al. / Atherosclerosis 230 (2013) 336e346344showed lower IMT compared to controls [71]. IMT is a commonly
used predictor for CVD, although evidence does so far not
convincingly support that progression of IMT is associated with
CVD risk [74]. In contrast to the ﬁndings by Horenstein et al. [71], in
a genome wide association study, gene variants in ABCG8 were
found to be signiﬁcantly associated with increased serum PS con-
centrations and increased CVD risk [75]. However, as stated by Plat
et al. [76], it cannot be ruled out that this association may be an
epiphenomenon because plasma PS concentrations also reﬂect
cholesterol absorption and, therefore, the associationwith CVD risk
may be explained by increased absorption of cholesterol. Genser
et al. [23] recently published a meta-analysis of observational
studies that aimed to investigate the association between serum
sitosterol and campesterol concentrations and CVD risk. The indi-
vidual studies included in this meta-analysis showed conﬂicting
evidence. However, based on seventeen studies reporting either
plasma PS concentrations in CVD cases vs. controls or relative risks
for CVD, it was concluded that, overall, no association between
circulating PS (sitosterol and campesterol) and risk of CVD exists. In
our meta-analysis, the observed control-adjusted average changes
in plasma sitosterol and campesterol concentrations (2 and 5 mmol/
L, respectively) were at least smaller than the difference between
the upper and the lower tertiles of the sitosterol and campesterol
distributions (6 and 10 mmol/L, respectively) reported in the Genser
meta-analysis. Evidence from endpoint studies demonstrating a
reduced risk of CVD has so far not been generated with intake of PS.
This meta-analysis has some limitations that need to be
addressed. A considerable amount of heterogeneity was observed
among the studies, more for circulating sitosterol and campesterol
than for LDL-cholesterol and TC concentrations. Some of this het-
erogeneity could be explained by differences in PS dose, baseline PS
concentration and in PS composition. However, many other factors
could have induced variability between studies such as differences
in study designs, test products and study populations. In particular,
between-study differences in plasma PS concentrations may have
been induced by differences in analytical methods used to measure
plasma PS (i.e. differences in PS separation and detections
methods). For better comparison between studies, there is a clear
need for standardization of methods to measure plasma PS con-
centrations. Furthermore, the quality of the meta-analysis depends
on the quality of the studies that have been included. As such, we
had pre-deﬁned rigorous selection criteria in order to exclusively
retrieve studies that were suitable to answer our study objectives.
We have not considered the quality of each individual study due to
the rather subjective nature of such quality scoring. Finally, there is
considerable indication that publication bias was present; the
funnel plots suggested that studies reporting relatively small in-
creases in plasma PS concentrations with low precision were
lacking. In PS studies, determining changes in plasma PS concen-
trations is usually not the primary aim, and thus, it maywell be that
in some studies, blood samples were drawn to measure circulating
PS but were eventually not analyzed or reported due to unknown
reasons. In any case, given the observation that studies reporting
relatively small increases in plasma PS seemed lacking, our ﬁndings
are likely not underestimated. Despite these limitations, the cur-
rent meta-analysis provides a good overview of all evidence
available on this topic.
In summary, our meta-analysis including data from 41 ran-
domized controlled studies showed that intake of PS-enriched
foods (average PS dose was w1.6 g/d) increases circulating sitos-
terol and campesterol concentrations (2.24 and 5.00 mmol/L,
respectively) whilst reducing TC and LDL-cholesterol concentra-
tions (0.36 and 0.33 mmol/L, respectively). Overall, total PS
remained below 1% of total sterols circulating in the blood which is
far below levels seen in homozygous sitosterolemics. Since aconsiderable amount of heterogeneity was observed in plasma PS
concentrations amongst the included studies, attempts to harmo-
nize methods for measuring plasma PS concentrations should be
undertaken.
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